Mei Ming

机构：University of Chicago · ORCID：0000-0002-7150-6725

发表论文 52 篇 · 总被引 1537 次 · h-index 18

代表论文

• Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL (2017 · Blood Advances · 被引 133)
• Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL (2016 · Oncotarget · 被引 90)
• XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB (2018 · Molecular Cancer Therapeutics · 被引 47)
• Selective perrhenate/pertechnetate removal by a MOF-based molecular trap (2022 · Dalton Transactions · 被引 20)
• Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2 (2021 · Blood Advances · 被引 17)
• Bridging the Gap: Interdepartmental Quality Improvement and Patient Safety Curriculum Created by Hospital Leaders, Faculty, and Trainees (2018 · Journal of Graduate Medical Education · 被引 15)